An evaluation of the efficacy and safety of doxazosin in hypertension associated with renal dysfunction

[1]  I. Takasaki,et al.  Hemodynamic Effects of Tilisolol, a New β-Adrenergic Blocking Agent with Vasodilating Property, and Doxazosir, a New α-Adrenergic Blocking Agent, in Essential Hypertension , 1988 .

[2]  A. Fujimura,et al.  Pharmacokinetic and Pharmacological Properties of Doxazosin Mesilate in Japanese Healthy Adult Volunteers , 1988 .

[3]  Bailey Rr,et al.  Effect of doxazosin on blood pressure and renal haemodynamics of hypertensive patients with renal failure. , 1986 .

[4]  E. Begg,et al.  Pharmacokinetics and effect on blood pressure of doxazosin in normal subjects and patients with renal failure , 1986, Clinical pharmacology and therapeutics.

[5]  J. Milson,et al.  The antihypertensive effects of doxazosin: a clinical overview. , 1986, British journal of clinical pharmacology.

[6]  P. Lund-johansen,et al.  Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise. , 1986, British journal of clinical pharmacology.

[7]  P. Meredith,et al.  Clinical pharmacological studies with doxazosin. , 1986, British journal of clinical pharmacology.

[8]  J. Reid,et al.  The metabolism and kinetics of doxazosin in man, mouse, rat and dog. , 1986, British journal of clinical pharmacology.

[9]  M. Davey,et al.  The alpha 1-adrenoceptor antagonist profile of doxazosin: preclinical pharmacology. , 1986, British journal of clinical pharmacology.

[10]  P. D. de Leeuw,et al.  Acute renal effects of doxazosin in man. , 1986, British journal of clinical pharmacology.